Insider Buying Hot‑Spot: CEO Aminov’s Recent RSU Purchase
The latest filing on March 30, 2026 shows CEO Aminov Erez acquiring 83,500 restricted‑stock units (RSUs) at zero cash cost—an event that comes on the heels of the company’s successful Phase 1 trial of Ketamir‑2. The RSUs, vesting immediately on the grant date, signal confidence from the top executive that Mira’s near‑term milestones will translate into tangible shareholder value. For investors, the timing is noteworthy: the stock is trading near its 52‑week low, and the company’s market cap hovers $43 million. Aminov’s move is a bullish endorsement that could help lift the stock out of a recent trough.
What This Means for Shareholders
Aminov’s sizable purchase—together with a series of option grants and large stock purchases over the past year—suggests a long‑term commitment to Mira’s pipeline. The CEO has been buying more shares than he has sold, accumulating over $4 million in equity through a mix of common stock and options. This pattern aligns with a company on the cusp of a Phase 2 IND submission, where positive data could unlock additional capital from institutional investors. For the market, Aminov’s action may reduce perceived agency risk and signal that management believes the company’s valuation is below its intrinsic worth, potentially creating a catalyst for a rebound.
A Profile of Aminov Erez
Aminov Erez, CEO and Chairman, has a history of aggressive equity accumulation. Over the past 18 months, he has executed several large option grants (up to 3 million shares) and common‑stock purchases that have steadily increased his holdings to more than 3.5 million shares. Notably, his most recent transaction—buying 83,500 RSUs—adds a new layer to his equity profile, reflecting a shift from cash‑based purchases to grant‑based compensation. This transition coincides with the board’s milestone‑based bonus package, indicating that management is tying future upside to clinical milestones. Historically, Aminov has sold only a modest portion of his holdings (e.g., the 613,595‑share sale at $2.11 in October 2025), suggesting he is not looking to liquidate but rather to reinforce his stake.
Strategic Context
Mira’s pipeline is currently centered on the NMDA receptor modulator Ketamir‑2 and the cannabinoid analogue MIRA‑55, both targeting chronic pain and anxiety. The Phase 1 data—no serious adverse events—position the company to file a Phase 2a IND in early 2026. The recent acquisition of SKNY Pharmaceuticals expands the portfolio with SKNY‑1, an oral therapeutic for metabolic pathways. Aminov’s RSU grant is part of a broader strategy to attract and retain talent, align incentives, and prepare the company for a potential FDA submission and subsequent funding rounds. For investors, these insider actions underscore a belief that Mira’s current valuation does not fully capture the upside from upcoming clinical milestones and potential strategic collaborations.
Bottom Line
Aminov Erez’s purchase of RSUs on March 30, 2026 signals strong internal confidence ahead of a critical regulatory milestone. The CEO’s consistent accumulation of equity, combined with recent grant‑based compensation, suggests he expects a significant increase in shareholder value as Mira progresses through Phase 2. While the stock remains volatile—trading near a 52‑week low—insider buying provides a positive signal that could attract new investors and support a price recovery as the company advances its pipeline and explores partnership opportunities.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-03-30 | Aminov Erez (Chief Executive Officer) | Buy | 83,500.00 | N/A | Restricted Stock Units |
